Miller Edward's Form 4/A amendment
AmendedKalaris Therapeutics, Inc. (KLRS) · filed Oct 26, 2022
- Accession no.
- 0000899243-22-034265
- Filed
- Oct 26, 2022
- Trade date
- Oct 20, 2022
- Filing delay
- 6 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Oct 24, 2022
This filing lists 1 non-derivative transaction. Open-market sales total $5.18K. It was filed 6 days after the trade.
This amendment replaces 0000899243-22-034056 (filed Oct 24, 2022).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Miller EdwardCIK 0001619252 | Officer (General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 20, 2022 | Common Stock | SSaleDisposed | −553 | $9.36F2 | −$5,176.08 | 249,377 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4/A is being filed correct the transaction date reported in the original Form 4 filed on October 24, 2022.